
By Gauri Tawde
CMC and Finance in emerging biotech companies are important partners, but they often find themselves at odds with one another. Complex CMC programs are dynamic, often changing substantially, and require large investments. Similarly, the financing environment in many companies continually evolves and may impact the speed at which technical CMC activities can take place. It can be difficult to capture the implications of those changes in a manner that the other function can use. In many cases, CMC and Finance leaders need a “bridge” to close the gap and align their functions.
The event opened with Converge Managing Director Todd Applebaum identifying the natural tension between CMC and Finance leaders that arises mostly from differences in perspective and language between these functions.
In this kind of a volatile environment, the CMC and Finance teams need to be in sync with each other.
Our guest speaker, Hugh Wight, a manufacturing executive with 20+ years of experience in pharmaceutical and biologics development, validation, and quality assurance, along with Converge Consultant Ash Pandit, shared a ‘CMC-Finance Bridge’ approach that proves effective in opening a connection between CMC and Finance. The CMC-Finance Bridge uses a CMC program management toolkit and project plans, combined with roles and responsibilities for CMC and Finance, and communications processes that allow the FP&A team to quickly integrate new information from CMC. Hugh and Ash presented a version of the Bridge using MS Project to build the CMC project plan, which then fed an automated CMC-FP&A bridge between the project plan and budgeting spreadsheets.
Hugh described the four phases of building the CMC-Finance Bridge as:
The CMC-Finance Bridge allows real-time impact assessment of changes in the CMC plan or strategy on financial forecasts. It provides the ability to view data by financial accounts, project phases, or functional departments, and serves as a single source of truth to align CMC and Finance baselines. It also enables scenario analysis to understand repercussions of changes in the financing environment and lead times on critical raw materials, equipment or other resources.
For help on maintaining alignment across your critical functional areas, contact our team at info@convergeconsulting.com today.
Subscribe to our mailing list for the latest insights on advanced therapy development, regulatory updates, industry trends, and upcoming events from Dark Horse Consulting Group.
We respect your privacy. Unsubscribe at any time. We will never sell your information.